Holen Sie sich die Stockscreener-App
28.77
0.91%
0.26
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4%Should You Sell? - MarketBeat
A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism - Sahm
MLYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Citigroup Inc. - MarketBeat
Chart Watch: Can Mineralys Therapeutics Inc expand its profit marginsJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
MLYS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Stock Traders Buy High Volume of Mineralys Therapeutics Call Options (NASDAQ:MLYS) - MarketBeat
Biotech Mineralys gives new hire 27,920 options, 20,940 restricted stock units - Stock Titan
Should Mineralys’ New Shelf Registration and ESOP Offering Reshape How MLYS Investors View Its Capital Strategy? - Sahm
Investment Recap: How does Mineralys Therapeutics Inc score in quality rankingsMarket Risk Analysis & High Accuracy Trade Alerts - baoquankhu1.vn
MLYS Technical Analysis & ETF Price Forecast - Intellectia AI
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Biotech Gem with 77% Upside Potential - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Greenland Capital Management LP - MarketBeat
Mineralys (MLYS) director receives stock option and RSU grants - Stock Titan
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics (MLYS) director awarded options and RSUs in Form 4 - Stock Titan
Mineralys Therapeutics Inc options imply 21.7% move in share price post-earnings - TipRanks
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505 - Investing.com Nigeria
Rodman sells Mineralys Therapeutics (MLYS) stock for $11,505 By Investing.com - Investing.com UK
David Malcom Rodman Sells 417 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Trial Recognition Highlights NDA Path And Dilution Considerations - Yahoo Finance
Mineralys Therapeutics Grants Inducement Equity Awards to Two New Employees - MyChesCo
Mineralys Therapeutics, Inc. (MLYS): An 85.82% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance
Breakouts Watch: What’s Mineralys Therapeutics Inc.’s historical returnJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Big Picture: Is SCHWPRD attractive for institutional investorsProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Momentum Shift: How does Mineralys Therapeutics Inc score in quality rankingsPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Why (MLYS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How sensitive is Mineralys Therapeutics Inc. to inflationJuly 2025 EndofMonth & Verified Short-Term Trading Plans - mfd.ru
What are the future prospects of Mineralys Therapeutics Inc.Market Growth Report & Verified Stock Trade Ideas - mfd.ru
Mineralys Therapeutics MLYS officer sells $569k in stock - Investing.com Nigeria
David Malcom Rodman Sells 14,055 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS officer sells $569k in stock By Investing.com - Investing.com UK
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys Therapeutics (MLYS) insider files to sell 14,055 shares - Stock Titan
Mineralys Therapeutics Breaks Below 200-Day Moving AverageNotable for MLYS - Nasdaq
How strong is Mineralys Therapeutics Inc. stock balance sheetInsider Selling & Daily Profit Focused Screening - mfd.ru
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 6,349 Shares - MarketBeat
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys Therapeutics (MLYS) insider plans NASDAQ sale after option exercise - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Is Mineralys Therapeutics Inc. a top pick in the sector2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Candriam S.C.A. - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 60% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
How cyclical is Mineralys Therapeutics Inc.’s revenue streamJuly 2025 Chart Watch & Verified Stock Trade Ideas - mfd.ru
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS) - MarketBeat
Panic Selling: How sensitive is Mineralys Therapeutics Inc to inflationJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is Mineralys Therapeutics Inc. stock a defensive play in 20252025 Fundamental Recap & Low Drawdown Momentum Ideas - mfd.ru
Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday - MarketBeat
Profit Review: How sensitive is Mineralys Therapeutics Inc to inflation2025 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):